Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 + Apatinib + Fluzoparib in TNBC
NCT03945604Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jun 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camrelizumab, Rivoceranib and fluzoparib in triple-negative breast cancer (TNBC), sponsored by Hengrui. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Jun 2019; status: completed.
02
Drugs
camrelizumabRivoceranibfluzoparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03945604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945604.